Trial Profile
Phase II Study of Imatinib Mesylate and Gemcitabine for Recurrent/Metastatic Non-Small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Apr 2011 Actual patient number (17) added, as reported by ClinicalTrials.gov.
- 17 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2009 Planned number of patients changed from 48 to 53 as reported by ClinicalTrials.gov.